Pharma: Page 39
-
Permission granted by GoodRx
Sponsored by GoodRxInflation is forcing prioritization of healthcare spending — are you ready?
Inflation means your customers' money doesn't travel as far as it did a few weeks ago.
April 18, 2022 -
AbbVie, Genmab, with new data, prep FDA application for dual-acting cancer drug
Fresh trial results intensify competition with Roche to deliver the first lymphoma drug that marries antibody technology with an immunotherapy pathway.
By Jonathan Gardner • April 14, 2022 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Md Saiful Islam Khan via Getty Images
UK bid to battle antibiotic resistance yields first subscription-style plan
Pfizer and Shionogi could receive 10 million pounds, or about $13 million, a year for new antibiotics. International participation might be needed to further spur development, however.
By Jonathan Gardner • April 12, 2022 -
Maddie Meyer via Getty Images
Pfizer, Moderna name new finance chiefs amid surging revenue
Pfizer is bringing in former Lowe's and CVS Health executive David Denton, while Moderna hired Jorge Gomez, previously CFO at Cardinal Health. Both take the reins as their new companies face strategic questions.
By Jonathan Gardner • April 11, 2022 -
Tetra Images via Getty Images
Sponsored by Avanir Pharmaceuticals, Inc.Data and compassion: How the pharma industry prepared me for leadership through Covid
Leading through a pandemic is no easy feat but this pharmaceutical company's CEO led his organization not only from his head, but also from his heart.
By Wa’el Hashad, President & CEO, Avanir Pharmaceuticals, Inc. • April 11, 2022 -
Dan Kitwood via Getty Images
Pfizer buys a private biotech and its RSV drug research
The pharma company will add experimental RSV treatments to its pipeline through the deal, which is worth up to $525 million.
By Kristin Jensen • April 7, 2022 -
Novartis breast cancer drug approved for ultra-rare condition
The FDA's decision was based on real-world study data that indicated Novartis' Piqray could treat a cluster of conditions known collectively as PROS.
By Ned Pagliarulo • April 6, 2022 -
Merck counting on heart drugs to boost business next decade
The pharma expects peak cardiovascular drug sales to exceed $10 billion next decade, by which time current top sellers Keytruda and Gardasil will no longer be patent protected.
By Ned Pagliarulo • April 5, 2022 -
Permission granted by Novartis
Top Novartis executives to depart as company restructures
The Swiss pharma said its plan to merge multiple business units and cut yearly costs by $1 billion is likely to impact jobs, but declined to specify which roles and how many.
By Ben Fidler • April 4, 2022 -
Courtesy of Gilead Sciences
CAR-T treatment moves earlier as FDA widens approval of Gilead's Yescarta
Yescarta, previously cleared only for use in treating late-stage lymphoma, can now be used after initial treatment has failed, a first for the cellular drugs.
By Ned Pagliarulo • April 4, 2022 -
Courtesy of Sanofi
Sanofi API spinout takes step toward market listing
French regulators have approved plans by Sanofi to list the new EUROAPI business on Euronext Paris beginning May 6.
By Ned Pagliarulo • April 1, 2022 -
Jeenah Moon via Getty Images
Pfizer inflammatory disease drug hits goal in second study
The drugmaker said etrasimod, an experimental medicine acquired via its Arena buyout, improved remission rates in the second of two studies meant to support its approval in ulcerative colitis.
By Ned Pagliarulo • March 29, 2022 -
Sarah Silbiger via Getty Images
FDA rejects Lilly and Innovent immunotherapy, sending signal to drugmakers
The regulator demanded the partners run another clinical trial to support approval of sintilimab, a decision that could have ripple effects for the development of cancer drugs in the U.S.
By Ben Fidler • March 24, 2022 -
Permission granted by Bristol-Myers Squibb
Bristol Myers melanoma drug approved by FDA in immunotherapy advance
Opdualag is first approved drug that works by targeting a protein called LAG-3 and the third type of "checkpoint inhibitor" the agency has cleared for cancer.
By Ned Pagliarulo • March 21, 2022 -
Permission granted by Emergent CDMO
Sponsored by Emergent CDMOFour key considerations to help prepare for the next public health threat
As Omicron cases continue to decline and hopes for a return to normalcy rise once again, it's tempting to let your guard down. Emergent team members reflect on lessons learned through COVID-19 and share four considerations to help prepare for the next public health threat.
March 21, 2022 -
Christopher Furlong via Getty Images
AstraZeneca pays $775M to settle patent dispute over Alexion drug
The pharma reached an accord with Roche subsidiary Chugai over Ultomiris, a drug AstraZeneca acquired when it bought Alexion for nearly $40 billion.
By Kristin Jensen • March 17, 2022 -
Deep Dive // Patent thickets
Two decades and $200 billion: AbbVie’s Humira monopoly nears its end
The first biosimilar copy of Humira is set to arrive in the U.S. next week, testing both AbbVie and the market potential for knockoff biologic drugs.
By Jonathan Gardner • Updated Jan. 27, 2023 -
Courtesy of Eli Lilly
With trial success in kidney disease, Lilly, Boehringer make case for broader use of diabetes drug
The positive results are the latest evidence supporting a broader role for so-called SGLT2 inhibitors, which started out as diabetes medicines but have since shown promise in a range of metabolic diseases.
By Jonathan Gardner • March 16, 2022 -
Courtesy of Sanofi
Sanofi lures Blackstone backing in unusual deal for multiple myeloma drug
Rather than fund development of a more convenient version of its blood cancer drug Sarclisa on its own, Sanofi has instead turned to Blackstone, which has fast become one of the sector's more active investors.
By Kristin Jensen • March 15, 2022 -
Erik S. Lesser via Getty Images
Merck bid to combine two top drugs for prostate cancer falls short
The pharma ended a large study of Keytruda and Lynparza early after disappointing results, a setback for a combination that research has suggested could treat a range of cancers.
By Ben Fidler • March 15, 2022 -
Retrieved from iStock.
Sponsored by VeradigmImplementing value-based care to drive success for life sciences companies
Value-focused solutions can help life sciences groups make the switch to value-based contracting.
March 14, 2022 -
AbbVie holds off another Humira challenger with Alvotech deal
A settlement will allow the Iceland-based drugmaker to launch its Humira copycat, currently under FDA review, in the U.S. beginning next July.
By Ned Pagliarulo • March 9, 2022 -
Permission granted by Bristol-Myers Squibb
In first, Bristol Myers wins FDA OK for Opdivo use before surgery in lung cancer
Opdivo's approval is another step in drugmaker efforts to establish immunotherapy drugs earlier in cancer treatment.
By Ben Fidler • March 7, 2022 -
Mateusz Bartkowiak (QIAGEN)
Sponsored by QIAGENA better way to explore TCGA data
See how we fixed the metadata problem in TCGA and get the data dictionary.
March 7, 2022 -
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
Roche, nearing major trial readouts, starts new Alzheimer's drug study
As Aduhelm sputters on the market, Roche aims to prove its experimental medicine can work better. A large, multi-year trial is part of that bet.
By Jonathan Gardner • March 3, 2022
Previous
